DoMore Diagnostics, a company leveraging artificial intelligence to make personalized cancer treatment decisions simple and accessible, has secured a $10.8M grant. The funding round marks a significant development for the firm, which is based on prominent international research.
The company's unique digital biomarkers predict patient outcomes from routine tumor tissue slides, designed for seamless integration into pathologists’ existing workflows. Its lead product, Histotype Px® Colorectal, is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma, which informs decisions on adjuvant chemotherapy following surgical resection.
.png&w=3840&q=75)
